Invitae (NYSE: NVTA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Invitae to related companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, risk, profitability and earnings.
Insider & Institutional Ownership
71.4% of Invitae shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 8.7% of Invitae shares are owned by insiders. Comparatively, 18.4% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a summary of current recommendations for Invitae and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Invitae currently has a consensus target price of $11.00, suggesting a potential upside of 64.42%. As a group, “Medical laboratories” companies have a potential upside of 10.40%. Given Invitae’s stronger consensus rating and higher possible upside, equities analysts clearly believe Invitae is more favorable than its peers.
Volatility and Risk
Invitae has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Invitae’s peers have a beta of 1.25, suggesting that their average stock price is 25% more volatile than the S&P 500.
This table compares Invitae and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Invitae and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Invitae||$68.22 million||-$123.38 million||-2.52|
|Invitae Competitors||$1.13 billion||$76.65 million||275.90|
Invitae’s peers have higher revenue and earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Invitae peers beat Invitae on 8 of the 13 factors compared.
Invitae Company Profile
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It also operates Patient Insights Networks, a platform for collecting, curating, coordinating, and delivering data from patients and clinicians; and CancerGene Connect, an end-to-end platform that is used for the collection, analysis, and management of patient family history information. Invitae Corporation serves patients, healthcare providers, and biopharma and advocacy partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.